Abstract: Excipient compositions including a combination of excipients for mucoadhesive pharmaceutical compositions that improve mucoadhesiveness power, as well as release of and adhesion time of suitable active pharmaceutical ingredients (APIs) are disclosed. The excipient compositions include an aqueous solution with a synergistic combination of polymers, such as, for example amylopectin, pullulan, hyaluronic acid, and tamarind xyloglucan, among others. These polymers have been demonstrated to improve the release of as well as the adhesion time of APIs onto mucosa membrane. Mucoadhesive pharmaceutical compositions that include excipient compositions include suitable APIs, such as, for example analgesics, anesthetics, anthelmintics, anti-allergic agents, anti-fungals, antihistamines, anti-inflammatory agents, antimigraine agents, and hormones, among others. Mucoadhesive pharmaceutical compositions including excipient compositions are employed in the treatment of a plurality of mucous membrane diseases.

Abstract: Formulations for oral transmucosal compositions that include aromatase inhibitors (AIs) in combination with transmucosal absorption enhancers are disclosed. Disclosed oral transmucosal compositions may be for immediate release or slow release, and may be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Disclosed oral transmucosal compositions may include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms may include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms may be: mucoadhesive liquids such as gel-forming liquid; gel-forming; semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of AIs. Disclosed oral transmucosal compositions may allow the delivery of AIs directly into the patient's bloodstream, thus providing high bioavailability of AIs; therefore, required dose may be lower.

Abstract: Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical composition which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion that can include sodium citrate, succinic acid, xylitol, glutamic acid, and ethylenediaminetetraacetic acid (EDTA), among others. Additionally disclosed pharmaceutical composition may include active pharmaceutical ingredients (API) such as antibiotics. Subsequently, the antibiotics agent may be ciprofloxacin, amikacin, tobramycin, colistin methate, or polymixin, among others. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response.

Abstract: Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and AI.

Abstract: Compositions and methods for testosterone booster injection solutions (TBIS) that includes testosterone cypionate in synergistic combination with anastrozole are disclosed. Disclosed TBIS may be administered for treating testosterone deficiency. Disclosed TBIS is an intramuscular injection. The therapeutic dosage and protocol varies, according to the individual person. Different formulations may be designed to provide higher or lower testosterone doses.

Abstract: Compositions and methods for treating bacterial, fungal, and yeast infections in wounds are disclosed. The disclosed poloxamer-based pharmaceutical composition includes a micronized poloxamer composition base combined with one or more suitable active pharmaceutical ingredients (APIs), such as, antibacterial or antifungal, thereby resulting in a synergistic effect for the APIs. The micronized poloxamer composition within poloxamer-based pharmaceutical composition includes poloxamer 407 and poloxamer 188. Poloxamer-based pharmaceutical composition exhibits a particle size average of about 50 ?m, which enhance APIs solubility. Additionally, poloxamer-based pharmaceutical composition can be delivered in a plurality of dosage forms, such as, powders, sprays, ointments, pastes, creams, lotions, solutions, and patches, among others.

Abstract: The present disclosure refers to topical pharmaceutical bases that include a synergistic combination of pracaxi oil, andiroba oil, copaiba balsam, and ucuuba butter. Further, these topical pharmaceutical bases are proposed for treating skin conditions in mammals, such as, for example wounds and scars. The topical pharmaceutical bases provide healing, moisturizing, anti-inflammatory, antibacterial, and antifungal effect. Additionally, the topical pharmaceutical bases enable an effective administration of specific active pharmaceutical ingredients (APIs), thereby improving treatment outcomes. Topical pharmaceutical compositions including the topical pharmaceutical bases increase the residence time of APIs within a wound or scar, thereby improving the penetration of APIs into the affected area. Also, the topical pharmaceutical bases provide relatively uniform distribution of the APIs within the topical pharmaceutical compositions.

Abstract: The present disclosure refers to transdermal pharmaceutical bases that include a synergistic combination of a silicone base with a natural permeation enhancement composition (NPE). Further, these transdermal pharmaceutical bases are proposed to treat ear diseases in mammals. The silicone base includes silicone, pracaxi oil, and seje oil. Additionally, the NPE composition includes one or more phospholipids, one or more oils rich in essential fatty acids, behenic acid, and oleic acid, one or more skin lipids, and one or more butters rich in linoleic acid and linolenic acid. The synergistic combination of aforementioned natural components exhibit enhanced healing properties, thereby providing organic acids with antioxidant, antibacterial, and antifungal properties. The transdermal pharmaceutical bases are employed to increase the residence time of the medicament in the ear canal, and increase the penetration of the APIs into the affected area, thereby enhancing treatment effectiveness.

Abstract: The present disclosure refers to topical pharmaceutical bases that possess scar healing properties. Further, these topical pharmaceutical bases are proposed for treating skin conditions, such as, for example keloids, hypertrophic scars, wounds, and burns, among others. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective scar and wound treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve healing effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating skin conditions.

Abstract: Intralesional injections including poloxamer compounds and anticancer drugs are disclosed. The combination of the poloxamer-based composition with chemotherapeutic agents within the disclosed intralesional injections provides a synergistic effect, thereby allowing lower dosages of the active drugs and enhancing the treatment effectiveness. The disclosed poloxamer-based intralesional injections are employed for treating different types of cancer in humans and other animal species. The disclosed intralesional injections can be used as the sole therapy or in combination with one or more additional therapies, such as, chemotherapy, electrotherapy, immunotherapy and/or radiation therapy. The disclosed intralesional injections can be employed in virotherapy and gene therapy treatments. The disclosed intralesional injections are designed for immediate release or controlled release of the active drugs. The disclosed intralesional injections are employed for local or systemic administration of active drugs.

Abstract: The present disclosure refers to topical pharmaceutical bases that possess anti-inflammatory properties. Further, these topical pharmaceutical bases are proposed for treating inflammatory disorders, such as swollen tissues within joints and muscles, and the like. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective anti-inflammatory treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve anti-inflammatory effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating inflammatory disorders.

Abstract: Formulations for transdermal pharmaceutical compositions including clomiphene-like selective estrogen receptor modulators (C-SERMs) in combination with transdermal penetration enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and are administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency in male hypogonadism or male infertility. Transdermal pharmaceutical compositions include a range of dosage forms, such as, for example solutions, liquid sprays, lotions, emulsions, creams, pastes, and ointments, among other dosage forms that exhibit transdermal properties, and provide transdermal delivery of C-SERMs. Transdermal pharmaceutical compositions will deliver C-SERMs through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of C-SERMs.

Abstract: The present disclosure relates to pharmaceutical compositions with increased skin permeability for treating ear disease in mammals. Disclosed pharmaceutical compositions are prepared as topical gels or as transdermal gels. The pharmaceutical compositions reduce ear inflammation and irritation produced by ear diseases or injuries (e.g., cauliflower ear, chronic otitis, and the like). The pharmaceutical compositions include a synergistic combination of pracaxi oil and seje oil. Additionally, the pharmaceutical compositions include phosphatidylcholine as a permeation enhancer. The combination of aforementioned natural components exhibits enhanced healing properties, thereby providing organic acids with antioxidant, antibacterial, and antifungal properties.

Abstract: The present disclosure refers to topical pharmaceutical bases that possess antiviral properties. Further, these topical pharmaceutical bases are employed for preventing a patient to be infected by viral diseases. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective antiviral treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve antiviral effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for preventing viral diseases.

Abstract: A pharmaceutical composition for the treatment of yeast and fungal infections is provided. The composition may include a micronized poloxamer composition as excipient and itraconazole as active pharmaceutical ingredient (API). The micronized poloxamer composition may include a combination of poloxamer 188 and poloxamer 407. Additionally, micronized poloxamer-based composition, used as a surfactant, may help to break out or disrupt the membrane of microorganisms' cells within biofilm, thus allowing APIs, such as itraconazole, to improve their action and effectiveness against fungus and yeast infections. Additionally, poloxamer-based composition may be delivered to the infected site by different administration routes, such as orally, topically, via nasal, lung inhalation, and transdermal delivery. Due to the synergistic effect of poloxamer-based composition, itraconazole may have improved solubility, and dispersibility, thus decreasing side effects and time of treatment.

Abstract: The present disclosure refers to heptyl glucoside included, as a natural solubilizer and as a skin penetration enhancer, in transdermal pharmaceutical compositions. Heptyl glucoside is a natural alkyl glycoside and a hydrotrope that improves solubility of active pharmaceutical ingredients (APIs), thereby enhancing skin permeability to APIs. Transdermal pharmaceutical compositions including heptyl glucoside allow lower APIs dosage requirements. Heptyl glucoside can be combined with at least one API and suitable ingredients to formulate transdermal pharmaceutical compositions with improved skin permeability, thereby promoting percutaneous absorption of APIs. Transdermal pharmaceutical compositions including heptyl glucoside can be formulated in a plurality of dosage forms, such as, a liquid, cream, paste, gel, lotion, patch (e.g., matrix and reservoir), tape, film former (e.g., plaster), and the like.

Abstract: The present disclosure refers to a synergistic blend of Konjac powder and Xanthan gum that is included, as a natural suspending agent, in oral pharmaceutical suspensions. Oral pharmaceutical suspensions comprising the synergistic blend are aqueous solutions. The synergistic blend, used as a suspension agent to suspend suitable active pharmaceutical ingredients (APIs), improves the stability of oral pharmaceutical suspensions, and helps in the formation of a thermo-reversible gel and shear thinning necessary to keep APIs suspended within oral pharmaceutical suspensions. The synergistic blend of Konjac powder and Xanthan gum has unique anti-flocculation properties, which improve the homogeneity of the oral pharmaceutical suspensions. Additionally, the blend provides a better texture and mouth feel.

Abstract: An antibiotic composition for the treatment of bacterial infections, especially in the respiratory tract is provided. The antibiotic composition may include a mixture of gentamicin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in a suitable apparatus where a low-frequency acoustic field may be applied to facilitate mixing. Antibiotic composition may be obtained in powder form, or in solution, and may be administered by inhalation or irrigation. In other embodiments, a topical formulation of the antibiotic inhalation or irrigation composition may be produced. In some embodiments, other suitable poloxamers, or sugar alcohols may be employed as excipients. Due to the synergistic effect of micronized poloxamer composition, antibiotic composition may provide improved solubility and bioavailability of gentamicin, thus decreasing side effects and time of treatment.

Abstract: The present disclosure refers to a synergistic blend of heptyl glucoside and olive oil derivatives, which is included as a natural solubilizer agent in transdermal compositions to improve API solubilization. Improved solubilization of APIs increases the absorption of APIs into the patient's bloodstream resulting in desired levels of hormones. Reduction of the amount of APIs within the transdermal compositions to achieve the desired levels of hormones will reduce symptoms of hormone deficiency. The synergistic blend within transdermal compositions functions as a solubilizer agent, which allows complete dissolution of hormones, improves water solubility and increases skin permeation. Hormones that can be used in transdermal compositions comprising the synergistic blend include systemically active hormones, which are delivered through the skin with the assistance of natural solubilizer agents and skin penetration enhancers to achieve a desired effect.

Abstract: Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with a clomiphene-like selective estrogen receptor modulator (C-SERM) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and C-SERM.